​

Tourmaline Bio (TRML) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TRML Stock Forecast

Tourmaline Bio (TRML) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $46.00, with a high of $50.00 and a low of $42.00. This represents a 131.16% increase from the last price of $19.90.

$10 $18 $26 $34 $42 $50 High: $50 Avg: $46 Low: $42 Last Closed Price: $19.9

TRML Stock Rating

Tourmaline Bio stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

TRML Price Target Upside V Benchmarks

TypeNameUpside
StockTourmaline Bio131.16%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$50.00$47.33
Last Closing Price$19.90$19.90$19.90
Upside/Downside-151.26%137.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2538---11
May, 2538---11
Apr, 2537---10
Mar, 2536---9
Feb, 2535---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 14, 2025H.C. Wainwright$50.00$18.80165.96%151.26%
Mar 06, 2025Wedbush$42.00$14.33193.09%111.06%
Dec 05, 2024Etzer DaroutBMO Capital$50.00$24.03108.07%151.26%
Mar 21, 2024Yatin SunejaGuggenheim$50.00$28.6174.76%151.26%
Mar 20, 2024Robyn KarnauskasTruist Financial$74.00$44.6765.66%271.86%
Mar 20, 2024Roger SongJefferies$72.00$44.6761.18%261.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 06, 2025WedbushOutperforminitialise
Dec 05, 2024BMO CapitalOutperforminitialise
Nov 04, 2024GuggenheimBuyBuyhold
Oct 15, 2024Cantor FitzgeraldOverweightinitialise
Sep 04, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.87$-2.89----
Avg Forecast$-3.70$-2.92$-3.52$-4.49$-4.49$-3.90
High Forecast$-2.49$-2.74$-1.78$-3.49$-2.97$-3.90
Low Forecast$-4.68$-3.49$-4.54$-5.75$-7.70$-3.90
Surprise %139.73%-1.03%----

Revenue Forecast

$5M $17M $29M $41M $53M $65M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$8.57M$10.00M$10.00M$61.10M
High Forecast--$8.57M$10.00M$10.00M$61.10M
Low Forecast--$8.57M$10.00M$10.00M$61.10M
Surprise %------

Net Income Forecast

$-75M $-61M $-47M $-33M $-19M $-5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.12M$-73.21M----
Avg Forecast$-17.03M$-14.80M$-14.99M$-21.92M$-25.32M$-18.51M
High Forecast$-11.84M$-13.02M$-8.43M$-16.56M$-14.11M$-18.51M
Low Forecast$-22.23M$-16.58M$-21.56M$-27.28M$-36.54M$-18.51M
Surprise %147.29%394.70%----

TRML Forecast FAQ

Is Tourmaline Bio stock a buy?

Tourmaline Bio stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tourmaline Bio is a favorable investment for most analysts.

What is Tourmaline Bio's price target?

Tourmaline Bio's price target, set by 7 Wall Street analysts, averages $46 over the next 12 months. The price target range spans from $42 at the low end to $50 at the high end, suggesting a potential 131.16% change from the previous closing price of $19.9.

How does Tourmaline Bio stock forecast compare to its benchmarks?

Tourmaline Bio's stock forecast shows a 131.16% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Tourmaline Bio over the past three months?

  • June 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Tourmaline Bio’s EPS forecast?

Tourmaline Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.52, marking a 21.80% increase from the reported $-2.89 in 2024. Estimates for the following years are $-4.49 in 2026, $-4.49 in 2027, and $-3.9 in 2028.

What is Tourmaline Bio’s revenue forecast?

Tourmaline Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $8.57M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10M, followed by $10M for 2027, and $61.1M for 2028.

What is Tourmaline Bio’s net income forecast?

Tourmaline Bio's net income forecast for the fiscal year ending in December 2025 stands at $-14.994M, representing a -79.52% decrease from the reported $-73.21M in 2024. Projections indicate $-21.918M in 2026, $-25.322M in 2027, and $-18.505M in 2028.